This company has been marked as potentially delisted and may not be actively trading. Histogenics (HSGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock HSGX vs. APT, MLSS, LGMK, YMAB, LXRX, VIGL, EHAB, DCTH, ABSI, and AQSTShould you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Alpha Pro Tech (APT), Milestone Scientific (MLSS), LogicMark (LGMK), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), Vigil Neuroscience (VIGL), Enhabit (EHAB), Delcath Systems (DCTH), Absci (ABSI), and Aquestive Therapeutics (AQST). Histogenics vs. Its Competitors Alpha Pro Tech Milestone Scientific LogicMark Y-mAbs Therapeutics Lexicon Pharmaceuticals Vigil Neuroscience Enhabit Delcath Systems Absci Aquestive Therapeutics Histogenics (NASDAQ:HSGX) and Alpha Pro Tech (NYSE:APT) are both small-cap surgical appliances & supplies industry companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Does the media refer more to HSGX or APT? In the previous week, Histogenics' average media sentiment score of 0.00 equaled Alpha Pro Tech'saverage media sentiment score. Company Overall Sentiment Histogenics Neutral Alpha Pro Tech Neutral Do institutionals & insiders have more ownership in HSGX or APT? 40.4% of Histogenics shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 19.7% of Histogenics shares are owned by insiders. Comparatively, 15.0% of Alpha Pro Tech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, HSGX or APT? Alpha Pro Tech has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHistogenicsN/AN/A-$8.64M-$0.79-1.28Alpha Pro Tech$58.56M0.87$4.19M$0.3414.24 Which has more volatility & risk, HSGX or APT? Histogenics has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500. Comparatively, Alpha Pro Tech has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Is HSGX or APT more profitable? Alpha Pro Tech has a net margin of 6.99% compared to Histogenics' net margin of 0.00%. Alpha Pro Tech's return on equity of 6.70% beat Histogenics' return on equity.Company Net Margins Return on Equity Return on Assets HistogenicsN/A -34.96% 18.40% Alpha Pro Tech 6.99%6.70%5.76% SummaryAlpha Pro Tech beats Histogenics on 6 of the 10 factors compared between the two stocks. Get Histogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSGX vs. The Competition Export to ExcelMetricHistogenicsSurgical Appliances & Supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.55M$26.67M$5.81B$9.76BDividend YieldN/AN/A4.39%4.06%P/E Ratio-1.2813.0831.3626.05Price / SalesN/A2.09387.8788.42Price / CashN/A12.8038.0259.36Price / Book-101.002.139.536.60Net Income-$8.64M-$5.31M$3.26B$265.65M Histogenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSGXHistogenicsN/A$1.01flatN/A-22.3%$95.55MN/A-1.2849APTAlpha Pro TechN/A$4.65-0.9%N/A-24.1%$50.52M$58.18M12.57120Short Interest ↑MLSSMilestone Scientific2.3556 of 5 stars$0.60-3.6%$1.25+107.7%-42.0%$47.24M$8.61M-8.6030Short Interest ↑Gap UpLGMKLogicMark0.5239 of 5 stars$0.00+12.8%N/A-99.9%$2.54M$9.88M0.0020Analyst RevisionGap UpYMABY-mAbs Therapeutics2.4817 of 5 stars$8.51flat$9.62+13.1%-37.9%$386.68M$87.68M-17.02150LXRXLexicon Pharmaceuticals2.0604 of 5 stars$1.11+4.7%$3.23+190.5%-35.0%$385.20M$31.08M-3.36140VIGLVigil Neuroscience1.8421 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340EHABEnhabit1.2095 of 5 stars$7.58+0.5%$8.67+14.3%-0.4%$382.21M$1.03B-2.8410,700DCTHDelcath Systems2.7862 of 5 stars$11.11+2.1%$24.50+120.5%+38.8%$380.60M$37.21M222.2060Short Interest ↑ABSIAbsci2.8855 of 5 stars$3.12+5.1%$8.08+159.0%-41.4%$378.85M$4.53M-3.32210AQSTAquestive Therapeutics2.1313 of 5 stars$4.01+6.1%$10.14+152.9%-10.8%$376.95M$57.56M-5.73160Positive NewsAnalyst Revision Related Companies and Tools Related Companies APT Competitors MLSS Competitors LGMK Competitors YMAB Competitors LXRX Competitors VIGL Competitors EHAB Competitors DCTH Competitors ABSI Competitors AQST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSGX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access